ProCE Banner Activity

CE

Maximizing Efficacy and Minimizing Toxicity of ADCs Targeting HER2, HER3, and TROP-2: Strategies for Oncology Pharmacists

Video

On-demand webcast of expert faculty presentation and case discussion on strategies for managing antibody–drug conjugates targeting HER2, HER3, and TROP-2, including their efficacy and related toxicities, for oncology pharmacy professionals. 

Pharmacists: 1.00 contact hour (0.1 CEUs)

Released: April 17, 2024

Expiration: April 16, 2025

Share

Faculty

Allison Butts

Allison Butts, PharmD, BCOP

Clinical Pharmacy Specialist, Breast Oncology
Pharmacist Manager, Oncology
Program Director, PGY2 Hematology/Oncology Pharmacy Residency
UK Healthcare
Lexington, Kentucky

Sandra Cuellar

Sandra Cuellar, PharmD, BCOP, FHOPA, FASHP

Clinical Oncology Pharmacist, UI Health
Clinical Associate Professor
University of Illinois at Chicago College of Pharmacy
Chicago, Illinois

Provided by

Provided by ProCE, LLC, in partnership with Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Partners

Clinical Care Options, LLC

ProCE Banner

Target Audience

This program is intended for oncology/hematology pharmacists and other clinical practice stakeholders caring for patients with solid tumor cancers. 

Program Learning Goal

The activity aims to improve learners’ knowledge, confidence, and competence in identifying and managing adverse events associated with antibody–drug conjugate therapies in solid tumor cancers. 

Learning Objectives

Upon completion of this activity, participants should be able to: 

  • Analyze clinical evidence supporting the use of ADCs targeting HER2, HER3, and TROP-2

  • Explain the structural, mechanistic, and unique characteristics of ADCs that contribute to differing toxicities and adverse event profiles

  • Identify strategies for managing common and serious toxicities to effectively monitor and proactively identify signs and symptoms of serious adverse events

  • Develop strategies to manage common and serious toxicities or adverse events associated with approved and emerging antibody–drug conjugate therapies

  • Apply knowledge of ADCs, clinical evidence, and guidelines to real-world patient case scenarios

Disclosure

ProCE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COIs) they may have with ineligible companies. All relevant COIs are thoroughly vetted and mitigated according to ProCE policy. ProCE is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Allison Butts, PharmD, BCOP

Clinical Pharmacy Specialist, Breast Oncology
Pharmacist Manager, Oncology
Program Director, PGY2 Hematology/Oncology Pharmacy Residency
UK Healthcare
Lexington, Kentucky

Allison Butts, PharmD, BCOP, has no relevant financial relationships to disclose.

Sandra Cuellar, PharmD, BCOP, FHOPA, FASHP

Clinical Oncology Pharmacist, UI Health
Clinical Associate Professor
University of Illinois at Chicago College of Pharmacy
Chicago, Illinois

Sandra Cuellar, PharmD, BCOP, FHOPA, FASHP: consultant/advisor/speaker: Mirati.

The planners and content peer reviewers from ProCE, LLC and Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1 hour. To successfully complete this activity and receive credit, participants must follow these steps during the period from April 17, 2024, through April 16, 2025:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Pharmacists

ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-0000-24-001-H01-P has been assigned to this home study application-based activity. This activity is approved for 1 contact hour (0.10 CEUs) in states that recognize ACPE providers. The activity is provided at no cost to participants. Completion of the evaluation and the post-test with a score of 65% or higher are required to receive CE credit. No partial credit will be given. Statements of completion will be issued online at www.ProCE.com, and proof of completion will be posted in NABP CPE Monitor profiles.